Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
Bantscheff M; Eberhard D; Abraham Y; Bastuck S; Boesche M; Hobson S; Mathieson T; Perrin J; Raida M; Rau C; Reader V; Sweetman G; Bauer A; Bouwmeester T; Hopf C; Kruse U; Neubauer G; Ramsden N; Rick J; Kuster B; Drewes G; Nature Biotechnology, 2007, vol. 25, issue 9, p 1035, ISSN 10870156. ISBN 10870156.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef